Seeking Alpha

Achillion (ACHN +4.6%) gains on a price target increase to $17 from $12 at Deutsche Bank. The...

Achillion (ACHN +4.6%) gains on a price target increase to $17 from $12 at Deutsche Bank. The firm says liver abstracts from Bristol-Myers (BMY +0.6%) and Abbott (ABT +0.1%) bode well for the future success of ACHN's two drug combo regimens for the treatment of hepatitus C virus. The firm made similar comments yesterday about Gilead (GILD +1.6%).
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|